Ixekizumab - Biologic Drug Details

Summary for ixekizumab

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Suppliers: see list	1
Recent Clinical Trials:	See clinical trials for ixekizumab

Recent Clinical Trials for ixekizumab

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
NYU Langone Health	PHASE2
Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.	PHASE3
Eli Lilly and Company	PHASE4

See all ixekizumab clinical trials

Pharmacology for ixekizumab

Mechanism of Action	Interleukin-17A Antagonists
Established Pharmacologic Class	Interleukin-17A Antagonist

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for ixekizumab Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for ixekizumab Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Eli Lilly And Company	TALTZ	ixekizumab	Injection	125521	10,065,011	2035-05-20	DrugPatentWatch analysis and company disclosures
Eli Lilly And Company	TALTZ	ixekizumab	Injection	125521	10,258,679	2035-04-14	DrugPatentWatch analysis and company disclosures
Eli Lilly And Company	TALTZ	ixekizumab	Injection	125521	10,266,597	2037-07-24	DrugPatentWatch analysis and company disclosures
Eli Lilly And Company	TALTZ	ixekizumab	Injection	125521	10,519,241	2036-08-01	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for ixekizumab Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Eli Lilly And Company	TALTZ	ixekizumab	Injection	125521	10,039,810	2035-05-15	Patent claims search
Eli Lilly And Company	TALTZ	ixekizumab	Injection	125521	10,111,968	2036-08-10	Patent claims search
Eli Lilly And Company	TALTZ	ixekizumab	Injection	125521	10,227,403	2036-05-02	Patent claims search
Eli Lilly And Company	TALTZ	ixekizumab	Injection	125521	10,273,252	2036-06-14	Patent claims search

International Patents for ixekizumab

Country	Patent Number	Estimated Expiration
Peru	20180798
Norway	340827
Israel	315743
China	103260647

Supplementary Protection Certificates for ixekizumab

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2016/037	Ireland		PRODUCT NAME: IXEKIZUMAB; REGISTRATION NO/DATE: EU/1/15/1085 20160425
122016000069	Germany		PRODUCT NAME: LXEKIZUMAB; REGISTRATION NO/DATE: EU/1/15/1085 20160425
272 2-2016	Slovakia		PRODUCT NAME: IXEKIZUMAB; REGISTRATION NO/DATE: EU/1/15/1085 20160428
1690040-9	Sweden		PRODUCT NAME: IXEKIZUMAB; REG. NO/DATE: EU/1/15/1085/001-006 20160428

Market Dynamics and Financial Trajectory for the Biologic Drug: Ixekizumab

Last updated: July 27, 2025

Introduction

Ixekizumab (brand name: Taltz) is a biologic therapy developed by Eli Lilly and Co., approved by the U.S. Food and Drug Administration (FDA) in 2016 for the treatment of plaque psoriasis. Since its launch, ixekizumab has gained traction in the psoriasis market due to its robust efficacy, favorable safety profile, and convenience of administration. This article presents a comprehensive analysis of the market dynamics and financial trajectory of ixekizumab, emphasizing key factors influencing its growth, competition, regulatory landscape, and future outlook.

Market Position and Key Indications

Ixekizumab is primarily indicated for moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis. Its mechanism involves targeting interleukin-17A (IL-17A), a cytokine central to inflammatory processes. Its high efficacy, with rapid onset of action and sustained skin clearance, has led to rapid adoption among dermatologists and rheumatologists.

The biologic's positioning hinges on its effectiveness over competitors like secukinumab (Cosentyx), brodalumab, and ustekinumab. Clinical trial data reveals superior or comparable efficacy, which has bolstered its market share. As of 2023, ixekizumab holds approximately 25-30% of the IL-17 inhibitor segment in the psoriasis market, indicating competitive strength but also highlighting ongoing contestation from rivals.

Market Drivers

1. Expanding Patient Population
   Psoriasis affects approximately 2-3% of the global population (~125 million people), with around 20-30% having moderate-to-severe disease suitable for biologic treatment [1]. The rising awareness, improved diagnostics, and expanding guidelines favor biologic therapy adoption, augmenting ixekizumab's market potential.

2. Clinical Advantages and Patient Preference
   Ixekizumab’s rapid onset (improvement within one week in some cases), high skin clearance rates, and quarterly dosing schedule (after initial injections) enhance patient adherence and satisfaction. These benefits translate into higher prescription rates, especially among biologic-naïve populations.

3. Regulatory and Reimbursement Landscape
   Robust approval across multiple countries, coupled with expanding reimbursement coverage for biologics, has eased access barriers. Regulatory agencies recognize the therapeutic value, which favors adoption and market growth.

4. Pipeline Expansion and New Indications
   Eli Lilly is investigating ixekizumab for additional indications, including Crohn’s disease and hidradenitis suppurativa, which could further diversify its market landscape and revenue streams.

Market Challenges and Competitive Landscape

Despite its strengths, ixekizumab faces hurdles:

• Intense Competition: The IL-17 inhibitor class is highly competitive. Secukinumab (Novartis) remains the leader, with broader indications and a longer market presence. Ustekinumab (Janssen) targeting IL-12/23 and emerging agents like bimekizumab (which inhibits IL-17A and IL-17F) threaten ixekizumab’s market share.

• Pricing Pressures and Biosimilars: As biologics come off patent (though substantial patent protections remain), biosimilars could impact pricing and revenues, especially in regions with cost-sensitive payers.

• Manufacturing and Supply Chain Risks: Biologics’ complex manufacturing processes necessitate robust supply chains; disruptions could affect availability and financial performance.

• Safety Profile Considerations: While generally well-tolerated, concerns about infections and rare adverse events require continuous pharmacovigilance. Safety issues could influence prescribing behaviors.

Financial Trajectory and Revenue Outlook

Since its debut, ixekizumab has demonstrated compelling financial performance:

• Sales Growth Trends: In 2022, Eli Lilly’s psoriasis franchise, powered largely by ixekizumab, generated approximately $3.2 billion globally, representing a 25% increase year-over-year [2]. Ixekizumab contributed significantly, with sales growing due to larger patient base and increased utilization.

• Market Penetration and Adoption: Early adoption was driven by dermatologists, with expanding use among rheumatologists for psoriatic arthritis. The quarterly dosing regimen, along with convenient administration devices, supports sustained utilization.

• Forecasted Revenue: Industry analysts project a compound annual growth rate (CAGR) of around 10-12% for ixekizumab over the next five years, reaching $7 billion globally by 2027, contingent upon continued efficacy, safety, and competitive positioning [3].

• Impact of Patent Expiry and Biosimilars: With patent protections expiring in key markets around 2029, revenues might plateau or decline unless Lilly innovates further, introduces biosimilars with differentiated features, or expands indications.

Strategic Initiatives Influencing Financial Outlook

Eli Lilly invests in:

• Line Extensions: Combination therapies or formulations that extend the product’s life cycle.
• Global Expansion: Increasing penetration in emerging markets like China, Brazil, and India, where psoriasis prevalence is rising and biologic access is improving.
• Biologics Diversification: Developing next-generation IL-17 inhibitors and dual cytokine inhibitors to maintain market relevance.

Regulatory and Market Trends

Global regulatory agencies are increasingly approving biosimilars and seeking pathways for rapid evaluation. For instance, in Europe, biosimilar secukinumab is available, which could influence ixekizumab's pricing and market share [4].

Moreover, the shift toward precision medicine and biomarker-driven therapies could impact the prescribing patterns and growth potential of specific biologics, including ixekizumab.

Conclusion

Ixekizumab's market dynamics are characterized by strong clinical performance, expanding indications, and competitive challenges. Its financial trajectory remains positive, driven by robust sales growth, global expansion, and high patient demand for effective therapies. However, upcoming patent expirations, biosimilar competition, and evolving market preferences necessitate strategic adaptation. Sustained investment in innovation, broader indication approval, and geographic expansion will be crucial for Eli Lilly to uphold ixekizumab’s market leadership and revenue performance over the coming years.

---

Key Takeaways

• Market Strengths: Ixekizumab's high efficacy, rapid onset, and convenient dosing underpin its strong market position within the IL-17 inhibitor segment.

• Growth Drivers: Increasing global psoriasis prevalence, expanding reimbursement policies, and new indications support continued revenue growth.

• Competitive Risks: Intense rivalry, biosimilar entry post-patent expiry, and safety concerns require strategic vigilance.

• Financial Outlook: Projected sustained growth, with revenues potentially reaching $7 billion globally by 2027, contingent upon market dynamics.

• Strategic Imperatives: Diversification into new indications, geographic expansion, and innovation are essential to preserve market share and revenue streams.

---

FAQs

1. What factors give ixekizumab a competitive edge over other IL-17 inhibitors?
   Its rapid efficacy, high skin clearance rates, and flexible quarterly dosing contribute to superior patient adherence and satisfaction, fostering competitive edge over rivals like secukinumab.

2. When do biosimilars for ixekizumab become available, and how could they impact revenue?
   Biosimilars are expected around 2029 in major markets like the U.S. and EU, potentially reducing pricing power and revenues unless Lilly introduces new formulations or indications.

3. Which markets present the greatest growth opportunities for ixekizumab?
   Emerging markets such as China, India, and Brazil offer significant potential due to rising psoriasis prevalence and evolving healthcare infrastructure.

4. What are the main challenges facing ixekizumab’s future success?
   Patent expiries, biosimilar competition, safety considerations, and market saturation are primary challenges.

5. How is Eli Lilly planning to sustain ixekizumab’s growth?
   Through pipeline expansion, geographic penetration, indication broadening, and formulation innovations to retain market relevance.

---

References

[1] Parisi R, et al. “Global Epidemiology of Psoriasis: A Systematic Review of Prevalence and Incidence”. J Invest Dermatol. 2013.

[2] Eli Lilly Q4 2022 Financial Report.

[3] Market Research Future. “Biologic Drugs Market Forecast”, 2023-2027.

[4] European Medicines Agency. “Biosimilars in Dermatology: Market Access and Regulations”. 2022.